ARRAYJET, the biomedical company, has begun work on developing its next generation of bio-printing technological solutions.

Following a recent over-subscribed founding round the Midlothian business has hired seven new recruits across its science, engineering and commercial units, taking staff levels to 25. Three additional engineering roles will be created later in 2017.

Arrayjet specialises in microarray technology, which enhances drug discovery programs and other life science research strategies.

The company said that ahead of the new product launch in 2018, it would continue to expand and grow its international sales development pipeline, which has seen it enter 27 countries.

Arrayjet works with leading university research and biomedical research institutes to increase the accuracy, speed and throughput of drug discovery sampling, using its range of instrumentation.

Iain McWilliam, chief executive officer, Arrayjet, said: “A recent heavily oversubscribed round of funding via Archangel Investment Syndicate and a strong year on year 25 per cent revenue growth is testament to our proven ability to develop and nurture new business.

“An appetite for new business and a belief in our business model underpinned 2016 as a year in which we continued a programme of successful expansion. Arrayjet is on a very sound footing as a profitable, expanding, Scottish-based and international player in the biomedical sector.”

Mike Rutterford from Archangel called Arrayjet “one of the shining beacons within the Scottish life sciences industry”, adding that its expansion plans underlined “just how vital this business is to the life sciences landscape in Scotland”.